Panacos Financial Statements From 2010 to 2025

PANC Stock  USD 0.0001  0.00  0.00%   
Panacos Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Panacos Pharmaceuticals' valuation are provided below:
Gross Profit
99 K
Market Capitalization
321.8 K
Revenue
99 K
Earnings Share
(0.01)
Quarterly Revenue Growth
(0.20)
We have found one hundred twenty available trending fundamental ratios for Panacos Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Panacos Pharmaceuticals' recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 1 M, whereas Enterprise Value is forecasted to decline to (3 M).

Panacos Pharmaceuticals Total Revenue

153,900

Check Panacos Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Panacos Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Total Revenue of 153.9 K or Research Development of 21.1 M, as well as many indicators such as Price To Sales Ratio of 22.04, Dividend Yield of 0.0 or PTB Ratio of 0.0799. Panacos financial statements analysis is a perfect complement when working with Panacos Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Panacos Stock
Check out the analysis of Panacos Pharmaceuticals Correlation against competitors.
For information on how to trade Panacos Stock refer to our How to Trade Panacos Stock guide.

Panacos Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets50.4 M64.1 M56.4 M
Pretty Stable
Other Current Liabilities2.8 M3.6 MM
Slightly volatile
Total Current Liabilities5.4 M6.6 M7.6 M
Slightly volatile
Total Stockholder Equity34.3 M33.2 M30.5 M
Pretty Stable
Other Liabilities679.2 K540.9 K643.3 K
Slightly volatile
Accounts Payable2.1 M3.4 M2.9 M
Very volatile
Cash28.1 M43.5 M35.7 M
Slightly volatile
Other Assets1.3 M1.4 M1.6 M
Slightly volatile
Long Term Debt22.7 M21.6 M18.3 M
Slightly volatile
Inventory1.3 M1.4 M1.6 M
Slightly volatile
Other Current Assets1.1 M1.2 M1.1 M
Pretty Stable
Total Liabilities32.4 M30.9 M26.9 M
Slightly volatile
Intangible Assets340.3 K358.2 K610.5 K
Slightly volatile
Common Stock371.2 K615.2 K509.3 K
Pretty Stable
Property Plant Equipment893.5 K940.5 K3.4 M
Slightly volatile
Short Term Investments10.1 M16.1 M13.2 M
Slightly volatile
Good Will318.4 K358.2 K390.5 K
Slightly volatile
Net Receivables176.4 K132.3 K156.2 K
Slightly volatile
Short and Long Term Debt288.2 K411.7 K342.2 K
Slightly volatile
Total Current Assets57.7 M61.1 M50.9 M
Slightly volatile
Short Term Debt288.2 K411.7 K342.2 K
Slightly volatile
Deferred Long Term Liabilities275.7 K381.8 K320.2 K
Slightly volatile

Panacos Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue153.9 K162 K2.7 M
Slightly volatile
Research Development21.1 M28.9 M24.6 M
Slightly volatile
Cost Of Revenue25.2 M33.7 M37.3 M
Slightly volatile
Selling General Administrative9.6 M14.8 M12.1 M
Slightly volatile
Gross Profit153.9 K162 K249.6 K
Slightly volatile
Total Operating Expenses30.5 M43.6 M36.1 M
Slightly volatile
Non Recurring1.1 M1.1 M3.2 M
Slightly volatile

Panacos Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures41 K43.2 K424.7 K
Slightly volatile
Total Cash From Financing Activities23.2 M23.7 M19.7 M
Slightly volatile
Total Cashflows From Investing Activities14.3 M13.6 M15.3 M
Slightly volatile
Other Cashflows From Investing Activities14.4 M13.7 M15.7 M
Slightly volatile
Sale Purchase Of Stock871.2 K917.1 K7.5 M
Slightly volatile
Change In Cash7.5 M4.3 M4.8 M
Slightly volatile
Depreciation558 K618.7 K517.7 K
Slightly volatile
Change To Operating Activities1.1 M1.1 M1.2 M
Slightly volatile
Change To Netincome4.1 M4.3 M4.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio22.0420.9921.6426
Slightly volatile
PTB Ratio0.07990.130.1339
Very volatile
Days Sales Outstanding206268275
Pretty Stable
Book Value Per Share0.590.621.5295
Slightly volatile
Average Payables2.3 M1.4 M1.5 M
Pretty Stable
Capex To Depreciation0.0660.06950.1392
Slightly volatile
PB Ratio0.07990.130.1339
Very volatile
ROIC0.360.40.4381
Slightly volatile
Inventory Turnover14.6117.0215.3891
Slightly volatile
Days Of Inventory On Hand26.3722.224.1036
Slightly volatile
Payables Turnover7.59.199.4646
Pretty Stable
Average Inventory873.9 K919.9 K925.9 K
Slightly volatile
Research And Ddevelopement To Revenue132125129
Slightly volatile
Capex To Revenue0.260.240.2633
Pretty Stable
Cash Per Share1.071.121.3889
Slightly volatile
Days Payables Outstanding39.0441.145.6721
Slightly volatile
Income Quality0.580.750.8081
Slightly volatile
Intangibles To Total Assets0.07790.05650.0628
Slightly volatile
Current Ratio3.684.925.0302
Pretty Stable
Tangible Book Value Per Share0.590.621.5295
Slightly volatile
Receivables Turnover1.341.411.6169
Slightly volatile
Shareholders Equity Per Share0.590.621.5295
Slightly volatile
Debt To Equity0.810.770.7298
Slightly volatile
Capex Per Share0.0010.0010.3384
Slightly volatile
Average ReceivablesM5.6 MM
Slightly volatile
Revenue Per Share0.00370.00391.3743
Slightly volatile
Interest Debt Per Share0.40.421.7658
Slightly volatile
Debt To Assets0.420.40.3597
Pretty Stable
Operating Cycle216268277
Pretty Stable
Price Book Value Ratio0.07990.130.1339
Very volatile
Price Earnings To Growth Ratio0.01590.01510.0157
Slightly volatile
Days Of Payables Outstanding39.0441.145.6721
Slightly volatile
Operating Profit Margin205195201
Slightly volatile
Company Equity Multiplier1.62.222.0107
Slightly volatile
Long Term Debt To Capitalization0.440.420.3811
Very volatile
Total Debt To Capitalization0.480.460.4209
Pretty Stable
Return On Capital Employed0.620.760.8003
Pretty Stable
Debt Equity Ratio0.810.770.7298
Slightly volatile
Ebit Per Revenue205195201
Slightly volatile
Quick Ratio3.644.925.0243
Pretty Stable
Cash Ratio2.763.513.5918
Pretty Stable
Days Of Inventory Outstanding26.3722.224.1036
Slightly volatile
Days Of Sales Outstanding206268275
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.950.91.017
Slightly volatile
Price To Book Ratio0.07990.130.1339
Very volatile
Fixed Asset Turnover0.190.20.1985
Slightly volatile
Debt Ratio0.420.40.3597
Pretty Stable
Price Sales Ratio22.0420.9921.6426
Slightly volatile
Asset Turnover0.00350.00370.029
Slightly volatile
Gross Profit Margin0.290.370.3894
Pretty Stable
Price Fair Value0.07990.130.1339
Very volatile

Panacos Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM993 K1.1 M
Very volatile

About Panacos Pharmaceuticals Financial Statements

Panacos Pharmaceuticals stakeholders use historical fundamental indicators, such as Panacos Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Panacos Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Panacos Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Panacos Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Panacos Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue162 K153.9 K
Cost Of Revenue33.7 M25.2 M
Research And Ddevelopement To Revenue 125.45  131.72 
Capex To Revenue 0.24  0.26 
Ebit Per Revenue 195.11  204.87 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Panacos Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Panacos Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Panacos Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Panacos Pharmaceuticals Stock:
Check out the analysis of Panacos Pharmaceuticals Correlation against competitors.
For information on how to trade Panacos Stock refer to our How to Trade Panacos Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Panacos Pharmaceuticals. If investors know Panacos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Panacos Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.20)
Return On Assets
(0.53)
Return On Equity
(1.69)
The market value of Panacos Pharmaceuticals is measured differently than its book value, which is the value of Panacos that is recorded on the company's balance sheet. Investors also form their own opinion of Panacos Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Panacos Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Panacos Pharmaceuticals' market value can be influenced by many factors that don't directly affect Panacos Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Panacos Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Panacos Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Panacos Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.